Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain
| Autor: | Richard Malamut, Maciej Gasior, Derek Moe, Martin E. Hale, Mary Bond |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Prescription Drug Misuse Chemistry Pharmaceutical macromolecular substances Abuse deterrent Abuse deterrence 03 medical and health sciences 0302 clinical medicine medicine Humans 030212 general & internal medicine Psychiatry United States Food and Drug Administration business.industry Public health Chronic pain Opioid-Related Disorders General Medicine medicine.disease United States Analgesics Opioid Opioid Prescription opioid Chronic Pain business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Pain Management. 6:497-508 |
| ISSN: | 1758-1877 1758-1869 |
| DOI: | 10.2217/pmt-2015-0005 |
| Popis: | Misuse, abuse and diversion of prescription opioid analgesics represent a global public health concern. The development of abuse-deterrent formulations (ADFs) of prescription opioid analgesics is an important step toward reducing abuse and diversion of these medications, as well as potentially limiting medical consequences when misused or administered in error. ADFs aim to hinder extraction of the active ingredient, prevent administration through alternative routes and/or make abuse of the manipulated product less attractive, less rewarding or aversive. However, opioid ADFs may still be abused via the intended route of administration by increasing the dose and/or dosing frequency. The science of abuse deterrence and the regulatory landscape are still relatively new and evolving. This paper reviews the current status of opioid ADFs, with particular focus on different approaches that can be used to deter abuse, regulatory considerations and implications for clinical management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|